Meeting Information

The 2017 ASCO Annual Meeting took place Friday, June 2 - Tuesday, June 6 in Chicago.

Press Releases

Monday “News of the Day” Briefing:

  • CAR T-Cell Therapy Sends Multiple Myeloma Into Lasting Remission (Abstract LBA3001)
    CHICAGO – In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of multiple myeloma upon receiving a new type of immunotherapy  ̶  chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or BCMA. Most patients had only mild side effects. Read the full release.
     
  • Early Research Suggests First Immunotherapy for Mesothelioma on the Horizon (Abstract LBA8507)
    CHICAGO – Malignant pleural mesothelioma or MPM is a rare cancer, but its incidence has been rising. This cancer is usually associated with asbestos exposure, and patients have a median life expectancy of only 13-15 months. All patients relapse despite initial chemotherapy, more than 50% of them within six months after stopping treatment. There are currently no effective therapeutic options for patients with MPM. Read the full release.
     
  • Research Suggests Possible New Treatment for EGFR-Positive Lung Cancer (Abstract LBA9007)
    CHICAGO – Findings from a phase III clinical trial point to a potential new treatment for patients newly diagnosed with advanced, epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). Compared to the EGFR inhibitor gefitinib (Iressa), one of the standard targeted medicines for this disease, second-generation EGFR inhibitor dacomitinib delayed cancer growth by a median of 5.5 months more. Read the full release.
     
  • Alectinib Halts Lung Cancer Growth More Than a Year Longer Than Crizotinib (Abstract LBA9008)
    CHICAGO – Findings from a phase III clinical trial point to a more effective initial treatment for patients with ALK-positive non-small cell lung cancer (NSCLC). Compared to the current standard of care crizotinib (Xalkori), the newer ALK inhibitor alectinib (Alecensa) halted cancer growth for a median of 15 months longer and caused fewer severe side effects. Read the full release.
     
  • Adding a Second HER2 Blocker May Lower Chance of Invasive Breast Cancer for Some Women (Abstract LBA500)
    CHICAGO – A phase III clinical trial of 4,805 women with HER2-positive breast cancer suggests adding a second HER2 targeted medicine, pertuzumab (Perjeta), to standard of care trastuzumab (Herceptin) after surgery may help, although the benefit is modest. Read the full release.

Sunday “News of the Day” Briefing:

  • Global Study Sets New Risk-Based Standard to Personalize Chemotherapy for Colon Cancer After Surgery (Abstract LBA1)
    CHICAGO – After surgery for lymph-node positive colon cancer (stage III), some patients may only need half of the long-standing standard course of chemotherapy. In an analysis of six clinical trials with over 12,800 patients, 3 months of chemotherapy was nearly as effective as 6 months in patients with relatively lower recurrence risk and caused fewer side effects, particularly nerve damage. Read the full release.
     
  • Web-Based System for Self-Reporting Symptoms Helps Patients Live Longer (Abstract LBA2)
    CHICAGO – A randomized clinical trial of 766 patients shows that a simple intervention  ̶  a web-based tool that enables patients to report their symptoms in real time, triggering alerts to clinicians  ̶  can have major benefits, including longer survival. Patients with metastatic cancer who used the tool to regularly report symptoms while receiving chemotherapy lived a median of 5 months longer than those who did not use the tool. Read the full release.
     
  • Olaparib Slows Growth of BRCA-Related Metastatic Breast Cancer (Abstract LBA4)
    CHICAGO – Findings from a phase III clinical trial of about 300 women may introduce PARP inhibitors as a new type of treatment for breast cancer. Compared to standard chemotherapy, the oral targeted medicine olaparib (Lynparza) reduced the chance of progression of advanced, BRCA-related breast cancer by 42%, delaying progression by about 3 months. Read the full release.

Saturday “News of the Day (Part I)” Briefing:

  • Pregnancy After Breast Cancer Does Not Increase Chance of Recurrence (Abstract LBA10066)
    CHICAGO – Findings from a retrospective study of 1,200 women provide reassurance to breast cancer survivors who are contemplating pregnancy. In the study, women who became pregnant after an early breast cancer diagnosis, including those with estrogen receptor (ER)-positive tumors, did not have a higher chance of cancer recurrence and death than those who did not become pregnant. Read the full release.
     
  • Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival (Abstract LBA3)
    CHICAGO – Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 men, abiraterone also more than doubled the median time until the cancer worsened, from 14.8 months to 33 months. Read the full release.
     
  • Abiraterone Slows Advanced Prostate Cancer, Helps Patients Live Longer (Abstract LBA5003)
    CHICAGO – A clinical trial of nearly 2,000 men shows that adding abiraterone acetate (Zytiga) to a standard initial treatment regimen for high-risk, advanced prostate cancer lowers the relative risk of death by 37%. The 3-year survival rate was 76% with standard therapy alone, but 83% with standard therapy plus abiraterone. This is the largest study of abiraterone as first-line therapy for advanced prostate cancer. Read the full release.

Saturday “News of the Day (Part II)” Briefing:

  • New Drug Shows Durable Efficacy Across Diverse Pediatric and Adult Cancers (Abstract LBA2501)
    CHICAGO – Scientists may have developed the first targeted, oral, tumor-type agnostic therapy – a cancer medicine that works comparably well across many kinds of cancer, regardless of patient age. In clinical trials of adults and children with 17 different types of advanced cancer, larotrectinib treatment resulted in responses in 76% of patients. Response to larotrectinib has been durable, with 79% of responses ongoing 12 months after starting treatment. Read the full release.
     
  • New Technology Dives Deep Into the Cancer Genome (Abstract LBA11516)
    CHICAGO – In a study of 124 patients with advanced breast, lung, and prostate cancers, a new, high-intensity genomic sequencing approach detected circulating tumor DNA at a high rate. In 89% of patients, at least one genetic change detected in the tumor was also detected in the blood. Overall, 627 (73%) genetic changes found in tumor samples were also found in blood samples with this approach. Read the full release.
     
  • Routine Genomic Testing is Feasible, But Only a Subset of Patients Benefit (Abstract LBA100)
    CHICAGO – Genomic testing of tumor samples can enable personalized treatment selection, where targeted treatments are matched to genetic changes in the tumor. Although a growing number of patients with advanced cancers receive some genomic testing, comprehensive genomic testing is not yet routine care. Read the full release.

Friday “News of the Day” Briefing:

  • Psychological Intervention Lowers Survivors’ Fear of Cancer Recurrence (Abstract LBA10000)
    CHICAGO – About 50% of all cancer survivors and 70% of young breast cancer survivors report moderate to high fear of recurrence. The fear can be so distressing that it negatively affects medical follow-up behavior, mood, relationships, work, goal setting, and quality of life. Yet, interventions to alleviate this fear are lacking. Read the full release.
     
  • Psychological Intervention Relieves Distress in Patients With Advanced Cancer (Abstract LBA10001)
    CHICAGO – Advanced cancer triggers enormous distress and brings challenges that can seem overwhelming. Yet, most cancer centers lack systematic approaches to help patients and families manage the practical and emotional toll of advanced cancer. Read the full release.
     
  • Remote Therapy Program Improves Quality of Life, Lowers Distress After Cancer Diagnosis (Abstract LBA10002)
    CHICAGO – Most patients experience significant distress after they are diagnosed with cancer. This distress not only erodes quality of life, but can also negatively affect the course of the disease and the patient’s ability to tolerate treatment. Read the full release.
     
  • Steady Decrease in Severe Health Problems for Childhood Cancer Survivors (Abstract LBA10500)
    CHICAGO – Treatments for childhood cancer are often intense and carry the risk of lifelong health problems for survivors. An analysis of 23,600 childhood cancer survivors in the Childhood Cancer Survivor Study (CCSS), funded by the National Institutes of Health, found that the rate of severe health problems occurring five or more years after diagnosis has declined over time. Read the full release.
     
  • Low Testosterone After Testicular Cancer Is Common, Linked to Chronic Health Problems (Abstract LBA10012)
    CHICAGO – In a large study, 38% of 491 testicular cancer survivors had low testosterone levels, known as hypogonadism. Compared to survivors with normal testosterone levels, survivors with low testosterone were more likely to have a range of chronic health problems, including high blood pressure, diabetes, erectile dysfunction, and anxiety or depression. Read the full release.
     
  • A Single Radiation Treatment Sufficiently Relieves Spinal Cord Compression Symptoms (Abstract LBA10004)
    CHICAGO – A common complication in people with metastatic cancer, spinal cord compression is a major detriment to quality of life. Radiation treatment is widely used to relieve pain and other symptoms, but there is no standard recommended schedule, and approaches currently vary. Findings from a phase III clinical trial show that a single radiation treatment is as effective as a full week of radiation. Read the full release.

CancerLinQ: 

  • CancerLinQ Partners with FDA to Study Real-World Use of Newly Approved Cancer Treatments
    CHICAGO – CancerLinQ LLC today announced a long-term partnership with the U.S. Food and Drug Administration (FDA) that will harness cancer patient information and big data analytics to examine the real-world use of emerging and newly approved cancer therapies. Read the full release.
     
  • CancerLinQ and National Cancer Institute Announce Partnership to Enhance Patient Care and Strengthen Cancer Surveillance
    CHICAGO – CancerLinQ LLC and the National Cancer Institute (NCI) today announced a partnership to facilitate the exchange of information between CancerLinQ® participating oncology practices and NCI’s Surveillance, Epidemiology, and End Results (SEER) program, one of the primary sources of data on cancer incidence and survival in the United States. Read the full release

May 17 Presscast:

  • Chance of Colon Cancer Recurrence Nearly Cut in Half in People Who Eat Nuts (Abstract 3517)
    ALEXANDRIA, Va. – An observational study of 826 patients with stage III colon cancer showed that those who consumed two ounces or more of nuts per week had a 42% lower chance of cancer recurrence and 57% lower chance of death than those who did not eat nuts. Read the full release. 

  • Healthy Lifestyle After Colon Cancer Diagnosis Helps Patients Live Longer (Abstract 10006)
    ALEXANDRIA, Va. – A study of 992 patients with stage III colon cancer found that those who reported a healthy lifestyle during and following adjuvant (post-surgery) treatment had a 42% lower chance of death and a trend for lower chance of cancer recurrence than those who had less healthy lifestyles. Read the full release. 

  • Oral Chemotherapy Extends Survival by More Than a Year in Biliary Tract Cancer (Abstract 4006)
    ALEXANDRIA, Va. – A phase III randomized clinical trial of 447 patients with biliary tract cancers (BTCs, cancers of the bile duct and gallbladder) showed that giving capecitabine after surgery extends survival by a median of 15 months compared to surgery alone. Read the full release. 

  • Targeted Therapy Can Delay Recurrence of Intermediate-Stage Lung Cancer (Abstract 8500)
    ALEXANDRIA, Va. – The targeted therapy gefitinib appears more effective in preventing recurrence after lung cancer surgery than the standard of care, chemotherapy. Read the full release. 

  • HPV Vaccination May Reduce Oral HPV Infections – But Still Under-Utilized (Abstract 6003)
    ALEXANDRIA, Va. – In one of the first large studies to explore the possible impact of HPV vaccination on oral HPV infections, researchers found it may confer a high degree of protection. Read the full release. 

  • More Cancers Diagnosed at Early Stage Following Increase in Health Insurance Coverage (Abstract 6521)
    ALEXANDRIA, Va. – An analysis of nearly 273,000 patients showed that between 2013 and 2014 there was a 1% increase in the percentage of breast, lung, and colorectal cancers diagnosed at the earliest, most treatable stage. Read the full release. 

Press Program Announcement:

  • World’s Largest Clinical Cancer Research Meeting to Highlight Latest Advances in Patient and Survivor Care
    ALEXANDRIA, Va. – Studies spanning the spectrum of cancer prevention and care, from immunotherapy and precision medicine to survivorship, will be highlighted in the official Press Program for the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO). Read the full release.

Press Briefing Recordings

Meeting Publications

Media Resources

How Can We Help You?